Corinne Beinat1, Tom Haywood1, Yun-Sheng Chen1, Chirag B Patel1,2, Israt S Alam1, Surya Murty1,3, Sanjiv Sam Gambhir4,5. 1. Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, 943065, USA. 2. Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA. 3. Department of Bioengineering and Materials Science & Engineering, Bio-X, Stanford University, Stanford, CA, 94305, USA. 4. Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, 943065, USA. sgambhir@stanford.edu. 5. Department of Bioengineering and Materials Science & Engineering, Bio-X, Stanford University, Stanford, CA, 94305, USA. sgambhir@stanford.edu.
Abstract
PURPOSE: There is a strong, unmet need for superior positron emission tomography (PET) imaging agents that are able to measure biochemical processes specific to prostate cancer. Pyruvate kinase M2 (PKM2) catalyzes the concluding step in glycolysis and is a key regulator of tumor growth and metabolism. Elevation of PKM2 expression was detected in Gleason 8-10 tumors compared to Gleason 6-7 carcinomas, indicating that PKM2 may potentially be a marker of aggressive prostate cancer. We have recently reported the development of a PKM2-specific radiopharmaceutical [18F]DASA-23 and herein describe its evaluation in cell culture and preclinical models of prostate cancer. PROCEDURE: The cellular uptake of [18F]DASA-23 was evaluated in a panel of prostate cancer cell lines and compared to that of [18F]FDG. The specificity of [18F]DASA-23 to measure PKM2 levels in cell culture was additionally confirmed through the use of PKM2-specific siRNA. PET imaging studies were then completed utilizing subcutaneous prostate cancer xenografts using either PC3 or DU145 cells in mice. RESULTS: [18F]DASA-23 uptake values over 60-min incubation period in PC3, LnCAP, and DU145 respectively were 23.4 ± 4.5, 18.0 ± 2.1, and 53.1 ± 4.6 % tracer/mg protein. Transient reduction in PKM2 protein expression with siRNA resulted in a 50.1 % reduction in radiotracer uptake in DU145 cells. Small animal PET imaging revealed 0.86 ± 0.13 and 1.6 ± 0.2 % ID/g at 30 min post injection of radioactivity in DU145 and PC3 subcutaneous tumor bearing mice respectively. CONCLUSION: Herein, we evaluated a F-18-labeled PKM2-specific radiotracer, [18F]DASA-23, for the molecular imaging of prostate cancer with PET. [18F]DASA-23 revealed rapid and extensive uptake levels in cellular uptake studies of prostate cancer cells; however, there was only modest tumor uptake when evaluated in mouse subcutaneous tumor models.
PURPOSE: There is a strong, unmet need for superior positron emission tomography (PET) imaging agents that are able to measure biochemical processes specific to prostate cancer. Pyruvate kinase M2 (PKM2) catalyzes the concluding step in glycolysis and is a key regulator of tumor growth and metabolism. Elevation of PKM2 expression was detected in Gleason 8-10 tumors compared to Gleason 6-7 carcinomas, indicating that PKM2 may potentially be a marker of aggressive prostate cancer. We have recently reported the development of a PKM2-specific radiopharmaceutical [18F]DASA-23 and herein describe its evaluation in cell culture and preclinical models of prostate cancer. PROCEDURE: The cellular uptake of [18F]DASA-23 was evaluated in a panel of prostate cancer cell lines and compared to that of [18F]FDG. The specificity of [18F]DASA-23 to measure PKM2 levels in cell culture was additionally confirmed through the use of PKM2-specific siRNA. PET imaging studies were then completed utilizing subcutaneous prostate cancer xenografts using either PC3 or DU145 cells in mice. RESULTS: [18F]DASA-23 uptake values over 60-min incubation period in PC3, LnCAP, and DU145 respectively were 23.4 ± 4.5, 18.0 ± 2.1, and 53.1 ± 4.6 % tracer/mg protein. Transient reduction in PKM2 protein expression with siRNA resulted in a 50.1 % reduction in radiotracer uptake in DU145 cells. Small animal PET imaging revealed 0.86 ± 0.13 and 1.6 ± 0.2 % ID/g at 30 min post injection of radioactivity in DU145 and PC3 subcutaneous tumor bearing mice respectively. CONCLUSION: Herein, we evaluated a F-18-labeled PKM2-specific radiotracer, [18F]DASA-23, for the molecular imaging of prostate cancer with PET. [18F]DASA-23 revealed rapid and extensive uptake levels in cellular uptake studies of prostate cancer cells; however, there was only modest tumor uptake when evaluated in mouse subcutaneous tumor models.
Authors: Antonio Medrano; Josep Ma Fernández-Novell; Laura Ramió; Juan Alvarez; Erwin Goldberg; Ma Montserrat Rivera; Joan J Guinovart; Teresa Rigau; Joan E Rodríguez-Gil Journal: Mol Reprod Dev Date: 2006-03 Impact factor: 2.609
Authors: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: Hossein Jadvar; Li Xiankui; Antranik Shahinian; Ryan Park; Michel Tohme; Jacek Pinski; Peter S Conti Journal: Mol Imaging Date: 2005 Apr-Jun Impact factor: 4.488
Authors: Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley Journal: Nature Date: 2008-03-13 Impact factor: 49.962
Authors: Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Tom Haywood; Corinne Beinat; Gayatri Gowrishankar; Chirag B Patel; Israt S Alam; Surya Murty; Sanjiv Sam Gambhir Journal: Proc Natl Acad Sci U S A Date: 2019-05-23 Impact factor: 11.205
Authors: Corinne Beinat; Chirag B Patel; Tom Haywood; Surya Murty; Lewis Naya; Jessa B Castillo; Samantha T Reyes; Megan Phillips; Pablo Buccino; Bin Shen; Jun Hyung Park; Mary Ellen I Koran; Israt S Alam; Michelle L James; Dawn Holley; Kim Halbert; Harsh Gandhi; Joy Q He; Monica Granucci; Eli Johnson; Daniel Dan Liu; Nobuko Uchida; Rahul Sinha; Pauline Chu; Donald E Born; Geoffrey I Warnock; Irving Weissman; Melanie Hayden-Gephart; Mehdi Khalighi; Tarik F Massoud; Andrei Iagaru; Guido Davidzon; Reena Thomas; Seema Nagpal; Lawrence D Recht; Sanjiv Sam Gambhir Journal: Clin Cancer Res Date: 2021-09-02 Impact factor: 13.801